Skip to main content
. 2021 Feb 3;7:604826. doi: 10.3389/fcvm.2020.604826

Appendix 3.

Levels of soluble factors in study group pre and post-PMC.

Variables Pre-PMC group Post-PMC group P-value
Growth factors
GM-CSF 17 (13–21) 14 (12–18) 0.06
G-CSF 51 (33–77) 39 (31–56) 0.14
VEGF 23 (17–34) 17 (16–24) 0.03
FGF basic 24 (19–37) 22 (17–29) 0.01
PDGF 820 (199–1,810) 314 (210–1,033) 0.02
Proliferative factors
IL-2 17 (13–23) 14 (13–19) 0.01
IL-7 22 (20–23) 19 (18–23) 0.03
IL-15 20 (19–27) 20 (18–27) 0.03
Chemokines
CXCL10 1,280 (690–1,971) 1,088 (625–1,815) 0.05
CCL2 171 (69–357) 127 (48–324) 0.20
CCL3 375 (98–6,394) 212 (83–1,513) 0.06
CCL4 1,265 (736–2,304) 1,018 (576–1,586) 0.16
CCL11 2,533 (448–3,614) 1,966 (301–2,971) 0.01
CCL5 2,574 (1,738–2,995) 2,377 (1,732–3,004) 0.40
IL-8 65 (33–467) 29 (25–58) 0.14
Cytokines
TNF-α 22 (16–31) 19 (14–27) 0.10
IL-10 16 (13–22) 14 (12–24) 0.88
IL-5 18 (14–24) 15 (13–20) 0.01
IL-9 42 (34–49) 35 (30–40) 0.10
IL-1 β 23 (18–26) 17 (16–24) 0.02
IL-6 13 (13–18) 12 (11–15) 0.004
IL-12p70 16 (14–18) 14 (14–16) 0.01
IL-17 62 (29–93) 40 (31–73) 0.06
IFN-γ 23 (17–42) 21 (17–37) 0.13
IL-1ra 270 (155–1,057) 282 (143–654) 0.31
IL-4 136 (49–178) 99 (49–176) 0.01
IL-13 15 (13–18) 14 (13–16) 0.09

Data are presented as median and interquartile range (Q1–Q3). PMC, percutaneous mitral commissurotomy. Bold values represent statistically significant differences.